EC OKs Two New Uses for Novartis’ Cosentyx
The European Commission (EC) has approved Novartis’ Cosentyx (secukinumab) for treating ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Cosentyx is part of a new class of medicines called interleukin-17A (IL-17A) inhibitors to be made available in Europe for AS and PsA. These approvals follow earlier EC approval of Cosentyx for the first-line treatment of patients with moderate-to-severe plaque psoriasis.
The EC marketing authorizations for Cosentyx are applicable to all European Union (EU) and European Economic Area countries.
In total, 50 countries have approved Cosentyx for the treatment of moderate-to-severe plaque psoriasis, which includes the EU countries, Switzerland, Australia, the US, and Canada. In Europe, Cosentyx is approved for the systemic treatment of moderate-to-severe plaque psoriasis in adult patients. In the US, Cosentyx is approved as a treatment for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy (light therapy). In Japan, Cosentyx is approved for the treatment of moderate-to-severe plaque psoriasis and also for the treatment of PsA. In Ecuador, Cosentyx is approved for the treatment of PsA and AS.